Influence of plasminogen activator inhibitor type 1 on choroidal neovascularization

Vincent Lambert, Carine Munaut, Agnès Noël, Francis Frankenne, Khalid Bajou, Robert Gerard, Peter Carmeliet, Marie Paule Defresne, Jean Michel Foidart, Jean Marie Rakic

Research output: Contribution to journalArticle

78 Citations (Scopus)

Abstract

High levels of the plasminogen activators, but also their inhibitor, plasminogen activator inhibitor 1 (PAI-1), have been documented in neovascularization of severe ocular pathologies such as diabetic retinopathy or age-related macular degeneration (AMD). AMD is the primary cause of irreversible photoreceptors loss, and current therapies are limited. PAI-1 has recently been shown to be essential for tumoral angiogenesis. We report here that deficient PAI-1 expression in mice prevented the development of subretinal choroidal angiogenesis induced by laser photocoagulation. When systemic and local PAI-1 expression was achieved by intravenous injection of a replication-defective adenoviral vector expressing human PAI-1 cDNA, the wild-type pattern of choroidal angiogenesis was restored. These observations demonstrate the proangiogenic activity of PAI-1 not only in tumoral models, but also in choroidal experimental neovascularization sharing similarities with human AMD. They identify therefore PAI-1 as a potential target for therapeutic ocular anti-angiogenic strategies.

Original languageEnglish (US)
Pages (from-to)1021-1027
Number of pages7
JournalFASEB Journal
Volume15
Issue number6
DOIs
StatePublished - 2001

Fingerprint

Choroidal Neovascularization
Plasminogen Activator Inhibitor 1
angiogenesis
Macular Degeneration
eyes
diabetic retinopathy
therapeutics
plasminogen activator
Light Coagulation
Plasminogen Activators
Pathology
Diabetic Retinopathy
plasminogen activator inhibitors
photoreceptors
intravenous injection
Intravenous Injections
lasers
Lasers
Complementary DNA
mice

Keywords

  • Angiogenesis
  • Macular degeneration
  • Proteases
  • Retinal disease
  • Viral vector

ASJC Scopus subject areas

  • Agricultural and Biological Sciences (miscellaneous)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry
  • Cell Biology

Cite this

Lambert, V., Munaut, C., Noël, A., Frankenne, F., Bajou, K., Gerard, R., ... Rakic, J. M. (2001). Influence of plasminogen activator inhibitor type 1 on choroidal neovascularization. FASEB Journal, 15(6), 1021-1027. https://doi.org/10.1096/fj.00-0393com

Influence of plasminogen activator inhibitor type 1 on choroidal neovascularization. / Lambert, Vincent; Munaut, Carine; Noël, Agnès; Frankenne, Francis; Bajou, Khalid; Gerard, Robert; Carmeliet, Peter; Defresne, Marie Paule; Foidart, Jean Michel; Rakic, Jean Marie.

In: FASEB Journal, Vol. 15, No. 6, 2001, p. 1021-1027.

Research output: Contribution to journalArticle

Lambert, V, Munaut, C, Noël, A, Frankenne, F, Bajou, K, Gerard, R, Carmeliet, P, Defresne, MP, Foidart, JM & Rakic, JM 2001, 'Influence of plasminogen activator inhibitor type 1 on choroidal neovascularization', FASEB Journal, vol. 15, no. 6, pp. 1021-1027. https://doi.org/10.1096/fj.00-0393com
Lambert V, Munaut C, Noël A, Frankenne F, Bajou K, Gerard R et al. Influence of plasminogen activator inhibitor type 1 on choroidal neovascularization. FASEB Journal. 2001;15(6):1021-1027. https://doi.org/10.1096/fj.00-0393com
Lambert, Vincent ; Munaut, Carine ; Noël, Agnès ; Frankenne, Francis ; Bajou, Khalid ; Gerard, Robert ; Carmeliet, Peter ; Defresne, Marie Paule ; Foidart, Jean Michel ; Rakic, Jean Marie. / Influence of plasminogen activator inhibitor type 1 on choroidal neovascularization. In: FASEB Journal. 2001 ; Vol. 15, No. 6. pp. 1021-1027.
@article{a8251b5d6b4a42ee9735d133d38a6944,
title = "Influence of plasminogen activator inhibitor type 1 on choroidal neovascularization",
abstract = "High levels of the plasminogen activators, but also their inhibitor, plasminogen activator inhibitor 1 (PAI-1), have been documented in neovascularization of severe ocular pathologies such as diabetic retinopathy or age-related macular degeneration (AMD). AMD is the primary cause of irreversible photoreceptors loss, and current therapies are limited. PAI-1 has recently been shown to be essential for tumoral angiogenesis. We report here that deficient PAI-1 expression in mice prevented the development of subretinal choroidal angiogenesis induced by laser photocoagulation. When systemic and local PAI-1 expression was achieved by intravenous injection of a replication-defective adenoviral vector expressing human PAI-1 cDNA, the wild-type pattern of choroidal angiogenesis was restored. These observations demonstrate the proangiogenic activity of PAI-1 not only in tumoral models, but also in choroidal experimental neovascularization sharing similarities with human AMD. They identify therefore PAI-1 as a potential target for therapeutic ocular anti-angiogenic strategies.",
keywords = "Angiogenesis, Macular degeneration, Proteases, Retinal disease, Viral vector",
author = "Vincent Lambert and Carine Munaut and Agn{\`e}s No{\"e}l and Francis Frankenne and Khalid Bajou and Robert Gerard and Peter Carmeliet and Defresne, {Marie Paule} and Foidart, {Jean Michel} and Rakic, {Jean Marie}",
year = "2001",
doi = "10.1096/fj.00-0393com",
language = "English (US)",
volume = "15",
pages = "1021--1027",
journal = "FASEB Journal",
issn = "0892-6638",
publisher = "FASEB",
number = "6",

}

TY - JOUR

T1 - Influence of plasminogen activator inhibitor type 1 on choroidal neovascularization

AU - Lambert, Vincent

AU - Munaut, Carine

AU - Noël, Agnès

AU - Frankenne, Francis

AU - Bajou, Khalid

AU - Gerard, Robert

AU - Carmeliet, Peter

AU - Defresne, Marie Paule

AU - Foidart, Jean Michel

AU - Rakic, Jean Marie

PY - 2001

Y1 - 2001

N2 - High levels of the plasminogen activators, but also their inhibitor, plasminogen activator inhibitor 1 (PAI-1), have been documented in neovascularization of severe ocular pathologies such as diabetic retinopathy or age-related macular degeneration (AMD). AMD is the primary cause of irreversible photoreceptors loss, and current therapies are limited. PAI-1 has recently been shown to be essential for tumoral angiogenesis. We report here that deficient PAI-1 expression in mice prevented the development of subretinal choroidal angiogenesis induced by laser photocoagulation. When systemic and local PAI-1 expression was achieved by intravenous injection of a replication-defective adenoviral vector expressing human PAI-1 cDNA, the wild-type pattern of choroidal angiogenesis was restored. These observations demonstrate the proangiogenic activity of PAI-1 not only in tumoral models, but also in choroidal experimental neovascularization sharing similarities with human AMD. They identify therefore PAI-1 as a potential target for therapeutic ocular anti-angiogenic strategies.

AB - High levels of the plasminogen activators, but also their inhibitor, plasminogen activator inhibitor 1 (PAI-1), have been documented in neovascularization of severe ocular pathologies such as diabetic retinopathy or age-related macular degeneration (AMD). AMD is the primary cause of irreversible photoreceptors loss, and current therapies are limited. PAI-1 has recently been shown to be essential for tumoral angiogenesis. We report here that deficient PAI-1 expression in mice prevented the development of subretinal choroidal angiogenesis induced by laser photocoagulation. When systemic and local PAI-1 expression was achieved by intravenous injection of a replication-defective adenoviral vector expressing human PAI-1 cDNA, the wild-type pattern of choroidal angiogenesis was restored. These observations demonstrate the proangiogenic activity of PAI-1 not only in tumoral models, but also in choroidal experimental neovascularization sharing similarities with human AMD. They identify therefore PAI-1 as a potential target for therapeutic ocular anti-angiogenic strategies.

KW - Angiogenesis

KW - Macular degeneration

KW - Proteases

KW - Retinal disease

KW - Viral vector

UR - http://www.scopus.com/inward/record.url?scp=17744377410&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17744377410&partnerID=8YFLogxK

U2 - 10.1096/fj.00-0393com

DO - 10.1096/fj.00-0393com

M3 - Article

C2 - 11292663

AN - SCOPUS:17744377410

VL - 15

SP - 1021

EP - 1027

JO - FASEB Journal

JF - FASEB Journal

SN - 0892-6638

IS - 6

ER -